Gosset Year Founded
2012
Ownership
Public
Employees
~50
Stage
Phase 3
Modalities
Caliway Biopharmaceuticals General Information
Lead candidate CBL-514 demonstrated >300mL subcutaneous fat reduction vs placebo in Phase 2 study, with 85.7% of participants losing ≥150mL fat. In Dercum's disease Phase 2 study, 64.5% of painful lipomas showed >50% dimension reduction.
Drug Pipeline
CBL-514
Phase 3Key Partnerships
Caliway Biopharmaceuticals Funding
| Deal Type | Date | Amount | Status | Stage |
|---|---|---|---|---|
| Later Stage VC | Dec 14, 2023 | $97.4M | Completed | Phase 3 |
To view Caliway Biopharmaceuticals's complete valuation and funding history, request access »